Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
Conference Call and Webcast at 8:30AM Eastern Time
美國東部時間上午 8:30 的電話會議和網絡直播
NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Monday, May 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2024 financial results.
紐約，2024 年 5 月 2 日 /PRNewswire/ — Lucid 診斷公司 （納斯達克股票代碼：LUCD） （“Lucid” 或 “公司”）是一家處於商業階段的癌症預防醫學診斷公司，也是PAVMed Inc.（納斯達克股票代碼：PAVM，PAVMZ）的控股子公司，今天宣佈，它將在美國東部時間2024年5月13日星期一上午8點30分舉辦業務最新情況電話會議和網絡直播。在電話會議上，Lucid董事長兼首席執行官Lishan Aklog醫學博士將提供最新業務情況，包括公司運營和持續增長戰略概述。此外，Lucid的首席財務官丹尼斯·麥格拉思將討論公司2024年第一季度的財務業績。
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
該網絡直播將在公司網站luciddx.com的投資者關係欄目播出。或者，要通過電話參加電話會議，美國的來電者應撥打1-800-836-8184，國際聽衆應撥打1-646-357-8785。所有聽衆都應向接線員提供電話會議名稱 “Lucid Diagnostics 業務更新” 以供其加入。
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
電話會議結束後，將在公司網站luciddx.com的投資者關係欄目上重播30天。
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer deaths through early detection of esophageal precancer.
關於 Lucid 診斷
Lucid Diagnostics Inc. 是一家專注於癌症預防的商業階段醫療診斷公司，也是PAVMed Inc.（納斯達克股票代碼：PAVM）的子公司。Lucid專注於數百萬患有胃食管反流病（GERD）（也稱爲慢性胃灼熱）的患者，他們有患食道癌前症和癌症的風險。Lucid 的 ESOGuard 食道DNA測試使用其ESOCheck食管細胞採集設備對在簡短、無創的辦公室程序中採集的樣本進行，是第一種也是唯一一種市售診斷測試，能夠作爲高危患者的廣泛篩查工具，通過早期發現食管癌前病來降低癌症和癌症死亡的風險。
For more information, please visit and for more information about its parent company PAVmed, please visit .
欲了解更多信息，請訪問有關其母公司PavMed的更多信息，請訪問。
SOURCE Lucid Diagnostics
來源 Lucid Diagno
譯文內容由第三人軟體翻譯。